In NSCLC patients treated with PD-(L)1 inhibitors, the pretreatment percentage of CD28− CD57+ KLRG1+ cells among CD8 T cells, defined as the senescent immune phenotype (SIP), was correlated with poor outcomes [34]. Here, CD8A is linked to non-small cell lung carcinoma.